Literature DB >> 18780163

Optimisation of sampling windows design for population pharmacokinetic experiments.

Kayode Ogungbenro1, Leon Aarons.   

Abstract

This paper describes an approach for optimising sampling windows for population pharmacokinetic experiments. Sampling windows designs are more practical in late phase drug development where patients are enrolled in many centres and in out-patient clinic settings. Collection of samples under the uncontrolled environment at these centres at fixed times may be problematic and can result in uninformative data. Population pharmacokinetic sampling windows design provides an opportunity to control when samples are collected by allowing some flexibility and yet provide satisfactory parameter estimation. This approach uses information obtained from previous experiments about the model and parameter estimates to optimise sampling windows for population pharmacokinetic experiments within a space of admissible sampling windows sequences. The optimisation is based on a continuous design and in addition to sampling windows the structure of the population design in terms of the proportion of subjects in elementary designs, number of elementary designs in the population design and number of sampling windows per elementary design is also optimised. The results obtained showed that optimal sampling windows designs obtained using this approach are very efficient for estimating population PK parameters and provide greater flexibility in terms of when samples are collected. The results obtained also showed that the generalized equivalence theorem holds for this approach.

Entities:  

Mesh:

Year:  2008        PMID: 18780163     DOI: 10.1007/s10928-008-9097-1

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  13 in total

1.  Optimization of individual and population designs using Splus.

Authors:  Sylvie Retout; France Mentré
Journal:  J Pharmacokinet Pharmacodyn       Date:  2003-12       Impact factor: 2.745

2.  Experimental design and efficient parameter estimation in population pharmacokinetics.

Authors:  M K al-Banna; A W Kelman; B Whiting
Journal:  J Pharmacokinet Biopharm       Date:  1990-08

3.  Incorporating correlation in interindividual variability for the optimal design of multiresponse pharmacokinetic experiments.

Authors:  Kayode Ogungbenro; Gordon Graham; Ivelina Gueorguieva; Leon Aarons
Journal:  J Biopharm Stat       Date:  2008       Impact factor: 1.051

4.  Design in nonlinear mixed effects models: optimization using the Fedorov-Wynn algorithm and power of the Wald test for binary covariates.

Authors:  Sylvie Retout; Emmanuelle Comets; Adeline Samson; France Mentré
Journal:  Stat Med       Date:  2007-12-10       Impact factor: 2.373

5.  Practical experience and issues in designing and performing population pharmacokinetic/pharmacodynamic studies.

Authors:  L Aarons; L P Balant; F Mentre; P L Morselli; M Rowland; J L Steimer; S Vozeh
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

6.  Comparison of some practical sampling strategies for population pharmacokinetic studies.

Authors:  E N Jonsson; J R Wade; M O Karlsson
Journal:  J Pharmacokinet Biopharm       Date:  1996-04

7.  Some considerations on the design of population pharmacokinetic studies.

Authors:  Stephen Duffull; Tim Waterhouse; John Eccleston
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-08       Impact factor: 2.745

8.  Prospective evaluation of a D-optimal designed population pharmacokinetic study.

Authors:  Bruce Green; Stephen B Duffull
Journal:  J Pharmacokinet Pharmacodyn       Date:  2003-04       Impact factor: 2.745

9.  Optimum blood sampling time windows for parameter estimation in population pharmacokinetic experiments.

Authors:  Gordon Graham; Leon Aarons
Journal:  Stat Med       Date:  2006-12-15       Impact factor: 2.373

10.  Optimal design for multiresponse pharmacokinetic-pharmacodynamic models - dealing with unbalanced designs.

Authors:  Kayode Ogungbenro; Ivelina Gueorguieva; Oneeb Majid; Gordon Graham; Leon Aarons
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-02-07       Impact factor: 2.410

View more
  5 in total

1.  Population Fisher information matrix and optimal design of discrete data responses in population pharmacodynamic experiments.

Authors:  Kayode Ogungbenro; Leon Aarons
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-06-10       Impact factor: 2.745

2.  A sequential Monte Carlo approach to derive sampling times and windows for population pharmacokinetic studies.

Authors:  J M McGree; C C Drovandi; A N Pettitt
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-07-31       Impact factor: 2.745

3.  D optimal designs for three Poisson dose-response models.

Authors:  Alan Maloney; Ulrika S H Simonsson; Marloes Schaddelee
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-02-19       Impact factor: 2.745

4.  Dependence of treatment planning accuracy in peptide receptor radionuclide therapy on the sampling schedule.

Authors:  Christian Maaß; Jan Philipp Sachs; Deni Hardiansyah; Felix M Mottaghy; Peter Kletting; Gerhard Glatting
Journal:  EJNMMI Res       Date:  2016-03-25       Impact factor: 3.138

5.  Reduced and optimized trial designs for drugs described by a target mediated drug disposition model.

Authors:  A Brekkan; S Jönsson; M O Karlsson; A C Hooker
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-06-08       Impact factor: 2.745

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.